Biotechnology Focus Podcast

On this week’s show…A Canadian made Ebola vaccine enters the next phase of clinical trials, a major Canadian generics company goes into restructuring mode, a young VC fund based in Vancouver makes it known it wants to be a major player on the life sciences investment scene and two Canadian biotech company’s hit endpoints in their clinical trials, good news for one company and bad news for the other. We have this and more on this week’s show! Welcome to another episode of Biotechnology Focus Podcast. I’m your host Shawn Lawrence, hear to bring you a rundown of this week’s top stories on the Canadian biotech scene. Story 1 The Ebola outbreak of the last three years has winded down, but that hasn’t stopped researchers in their quest to develop new vaccines to treat it. In fact, a promising Ebola vaccine originally developed by the Public Health Agency of Canada is set to begin the next phase of clinical trials later this fall. As part of this next phase, the vaccine, VSV-EBOV, will be tested on volunteers seropo